Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 25;78(1):144-148.
doi: 10.1093/cid/ciad445.

Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Ismat Lotia Farrukh  1 , Nathalie Lachenal  2 , Malik M Adenov  3 , Saman Ahmed  1 , Yerkebulan Algozhin  4 , Sylvine Coutisson  2 , Epifanio Sánchez Garavito  5 , Catherine Hewison  6 , David Holtzman  7 , Helena Huerga  8 , Aleeza Janmohamed  1 , Palwasha Y Khan  1   9 , Gamarly Leblanc Jacques  10 , Nino Lomtadze  11 , Nara Melikyan  12 , Carole D Mitnick  13   14 , Gulnaz Mussabekova  3 , Elna Osso  13 , Sara Perea  15 , Fauziah Asnely Putri  16 , Mahmud Rashidov  4 , Michael L Rich  14   17 , Yekaterina Sakhabutdinova  4 , Kwonjune J Seung  14   17 , Assel Stambekova  4 , Dante Vargas Vásquez  18 , Molly F Franke  13 , Uzma Khan  1
Affiliations

Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Ismat Lotia Farrukh et al. Clin Infect Dis. .

Abstract

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.

Keywords: drug resistance; outcome; pregnancy; treatment; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. C. D. M. is a member of the Akagera Scientific Advisory Board (for development of lipid-based, nanoparticle delivery of anti-TB drugs; 1 payment made to Partners In Health as honorarium for this work). M. L. R. declares 5% of time spent on a National Institute of Allergy and Infectious Disease–sponsored grant (an observational study of multidrug-resistant TB treatment regimens) and 5% of time spent as an expert consultant on operational research for a World Health Organization EURO project. All remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Comment in

References

    1. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global burden of disease. Lancet Glob Health 2014; 2:e710–6. - PubMed
    1. Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC. Inclusion of key populations in clinical trials of new antituberculosis treatments: current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Med 2019; 16:e1002882. - PMC - PubMed
    1. Jones AJ, Mathad JS, Dooley KE, Eke AC. Evidence for implementation: management of TB in HIV and pregnancy. Curr HIV/AIDS Rep 2022; 19:455–70. - PMC - PubMed
    1. World Health Organization . WHO consolidated guidelines on tuberculosis. Module 4: treatment—drug-resistant tuberculosis treatment. Geneva, Switzerland: World Health Organization, 2020. - PubMed
    1. World Health Organization . WHO consolidated guidelines on tuberculosis. Module 4: treatment—drug-resistant tuberculosis treatment, 2022 update. Geneva,Switzerland: World Health Organization, 2022. - PubMed